Physician profile
Benjamin Basseri
NPI 1801059647
$37,020.35
in general payments reported to CMS, 2019-2025
38 companies · $3,834 in 2025
The $3,834 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,258 · 2020: $2,692 · 2021: $7,384 · 2022: $7,785 · 2023: $5,321 · 2024: $7,748 · 2025: $3,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,040.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Education | $111.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,988.62 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Ironwood Pharmaceuticals, INC | $5,374.87 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $4,717.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,651.82 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ferring Pharmaceuticals INC. | $2,531.05 | 2019-2023 | Rebyota |
| Janssen Biotech, INC. | $1,868.07 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Redhill Biopharma INC. | $1,766.78 | 2020-2024 | Talicia |
| Ardelyx, INC. | $894.29 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $651.16 | 2021-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $425.25 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $410.12 | 2024-2025 | Voquezna |
| Pfizer INC. | $389.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $388.78 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $378.88 | 2024-2025 | Vowst |
| Genzyme Corporation | $326.50 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $250.34 | 2021-2023 | |
| Celgene Corporation | $245.81 | 2021-2022 | |
| Romark Laboratories, Lc | $237.83 | 2019-2020 | |
| Braintree Laboratories, INC. | $218.29 | 2019-2025 | Sutab, Suflave |
| Amgen INC. | $173.90 | 2022-2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $170.80 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $122.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $114.58 | 2019 | |
| Alnylam Pharmaceuticals INC. | $100.72 | 2022-2025 | Givlaari, Oxlumo |
| Lilly USA, LLC | $94.19 | 2025 | Zepbound, Omvoh, Mounjaro |
| Exact Sciences Corporation | $83.80 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $70.66 | 2019 | |
| Alfasigma USA, INC. | $61.51 | 2020-2021 | |
| Vivus LLC | $47.49 | 2025 | Pancreaze |
| Shionogi INC | $43.96 | 2019-2020 | |
| My01 INC. | $43.56 | 2025 | My01 Continuous Compartmental Pressure Monitor |
| Celltrion USA INC. | $37.79 | 2024 | Zymfentra |
| Astrazeneca Pharmaceuticals Lp | $28.21 | 2019-2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2023 | Cyltezo |
| Gilead Sciences, INC. | $26.73 | 2024 | |
| Blueprint Medicines Corporation | $22.65 | 2023 | |
| Dova Pharmaceuticals | $18.68 | 2019 | |
| Boston Scientific Corporation | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Basseri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.